Stuart Poulton
EVP, Chief Development Officer · Karyopharm Therapeutics Inc.
- 2025
- Jul 30, 2026
- 8
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Stuart Poulton files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Richard A. Paulson - $137K in KPTI purchases and sales in the last 12 months
- Reshma Rangwala - $56K in KPTI purchases and sales in the last 12 months
- Sohanya Roshan Cheng - $46K in KPTI purchases and sales in the last 12 months
- Michael Mano - $36K in KPTI purchases and sales in the last 12 months
- Lori Macomber - $10K in KPTI purchases and sales in the last 12 months
- Kristin Abate - $8K in KPTI purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Stuart Poulton?
Stuart Poulton is a corporate insider, tracked as EVP, Chief Development Officer of Karyopharm Therapeutics Inc. (KPTI). InsiderAlpha holds 8 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Stuart Poulton submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Stuart Poulton been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($60K) across all tracked filings.
